Fibromyalgia Syndrome (FMS) is a chronic, idiopathic condition of widespread musculoskeletal pain, affecting primarily women. It is clinically characterized by chronic, non-articular, pain and a heightened response to pressure along with sleep disturbances, fatigue, bowel and bladder abnormalities, as well as cognitive dysfunction. The diagnostic criteria have changed repeatedly and there is neither definitive pathogenesis nor reliable diagnostic or prognostic biomarkers. Clinical and laboratory studies have provided evidence of altered central pain pathways. Recent evidence suggests the involvement of neuroinflammation with stress peptides triggering the release of neurosenzitizing mediators. The management of FMS requires a multidimensional approach including patient education, behavioral therapy, exercise, and pain management. Here we review recent data on the pathogenesis and propose new directions for research and treatment.
- The American Society for Pharmacology and Experimental Therapeutics